Why is "Acalabrutinib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-13 18:00:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Acalabrutinib entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-13 and was most recently seen on 2026-03-13.
Wikipedia Overview
Acalabrutinib, sold under the brand name Calquence, is an anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. It may be used both in relapsed as well as in treatment-naive settings.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL - OncLive
-
Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives - Wiley Online Library
-
Zanubrutinib Improves Survival vs Acalabrutinib in CLL - Oncology Nurse Advisor
-
Acalabrutinib May Weaken Rituximab’s Efficacy in CLL - The American Journal of Managed Care
-
FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL/SLL - Targeted Oncology
-
Acalabrutinib Approval Offers Time-Limited Approach in CLL/SLL - CancerNetwork
-
CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax - The ASCO Post
-
NICE recommends acalabrutinib combinations for MCL and CLL - Lymphoma Hub
-
Q&A: Large Study Compares Survival, Discontinuation Outcomes of Three BTK Inhibitors for CLL - Physician's Weekly
-
Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL - OncLive
-
Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL - The American Journal of Managed Care
-
Zanubrutinib Offers Clinical and Cost Benefits Over Acalabrutinib in R/R CLL - Targeted Oncology
-
FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL - OncLive
-
FDA Approval of Acalabrutinib Plus Venetoclax Brings an All-Oral, Fixed-Duration Option to Frontline CLL Care - OncLive
-
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up - OncLive
-
Zanubrutinib Extends TTNT, OS vs Acalabrutinib in Real-World R/R MCL - OncLive
-
Zanubrutinib Yields Real-World TTNT and OS Benefits vs Acalabrutinib in Treatment-Naive CLL - OncLive
-
Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL - OncLive
-
Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL - OncLive
-
Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL - OncLive
-
Real-World Evidence Backs Acalabrutinib in CLL Care - The American Journal of Managed Care
-
Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL - Medical Professionals Reference
-
Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD - OncLive
-
Acalabrutinib Gains Ground as Preferred BTK Inhibitor for CLL/SLL in Veterans Likely to Have Co-Morbidities - U.S. Medicine
-
Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL - Medscape
-
Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting - AstraZeneca
-
Oncologists Weigh Frontline BTK Inhibitor Strategies in CLL - Targeted Oncology
-
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL - The American Journal of Managed Care
-
Assessing Zanubrutinib vs Acalabrutinib Plus Venetoclax in Frontline CLL - OncLive
-
Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma - OncLive
-
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL - OncLive
-
Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL - OncLive
-
FDA OKs Acalabrutinib/Venetoclax in CLL/SLL - Oncology Nursing News
-
Anchored Analysis Comparing Zanubrutinib with Acalabrutinib-Venetoclax - OncLive
-
Case 1: Patient With BTK C481S Resistance Mutation Following Acalabrutinib/Obinutuzumab - The ASCO Post
-
FDA Approves Acalabrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - Consultant360
-
Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive CLL - OncLive
-
Zanubrutinib Tops Rivals in Real-World CLL Survival Study - The American Journal of Managed Care
-
Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL - Lymphoma Hub
-
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL - Targeted Oncology
-
Indirect Comparison Associates Zanubrutinib With Improved PFS in Treatment-Naive CLL - OncLive
-
Studies Use Real-World Data to Evaluate BTK Inhibitors in MCL, CLL; More Options Needed - The American Journal of Managed Care
-
ECHO trial 50-month follow-up results: ABR vs PBR in TN MCL - Lymphoma Hub
-
FDA Approval of CLL Combo Marks New Era for Leukemia Care - The American Journal of Managed Care
-
Frontline Acalabrutinib/Rituximab Followed By Brexu-Cel Shows Synergy and Safety in High-Risk MCL - OncLive
-
Acalabrutinib-Based Triplets Yield uMRD CRs in Previously Untreated Mantle Cell Lymphoma - OncLive
-
Cross-Trial Analysis Finds Zanubrutinib Outperforms Other BTKis in R/R CLL - Targeted Oncology
-
Efficacy and Cost Savings of Zanubrutinib in High-Risk R/R CLL - The American Journal of Managed Care
-
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains - The American Journal of Managed Care
-
Real-World Outcomes of Zanubrutinib vs Acalabrutinib in First-Line CLL - OncLive
-
FDA Approves Calquence Plus Venclexta for CLL and SLL - Cure Today
-
Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL - OncLive
-
Experts Consider New Data, New BTKi Choices in Frontline CLL - Targeted Oncology
-
Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature - Haematologica
-
Acalabrutinib a Safe Treatment Avenue for Older, Frail Patients With CLL - Targeted Oncology
-
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia - Oncology Central
-
Zanubrutinib May Benefit CLL/SLL Patients Intolerant of Other BTK Inhibitors - Oncology Nurse Advisor
-
Exploring Toxicities Driving BTK Inhibitor Selection in R/R CLL - Targeted Oncology
-
BTK Inhibitor Therapy Makes Inroads Into First-Line MCL - Hematology Advisor
-
FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL - MedPage Today
-
Real-World Analysis Sheds Light on Treatment Discontinuation With Covalent BTK Inhibitors in First-Line CLL - OncLive
-
Acalabrutinib Triplet Demonstrates High Response and Manageable Safety in Frontline Follicular Lymphoma - Targeted Oncology
-
Atrial Fibrillation and CLL: Assessing the Real-World Impact of Cardiovascular and Healthcare-Related Outcomes - Cancer Nursing Today
-
Individualizing Fixed-Duration Therapy in Treatment-Naive CLL - Targeted Oncology
-
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib - Nature
-
New All-Oral CLL Regimen Offers Fixed-Duration Treatment Option - Cure Today
-
AMPLIFY Redefines CLL Care: Adam Kittai, MD - The American Journal of Managed Care
-
First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events and Treatment Discontinuation - Cleveland Clinic
-
"Our Responsibility Should Be to Give You the Closest Thing to a Normal Life" - The American Journal of Managed Care
-
UK Lymphoma and Leukaemia Patients Access New Treatments - EMJ
-
ELEVATE-TN 6-year follow-up: Acalabrutinib + obinutuzumab in TN CLL - Lymphoma Hub
-
FDA Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients With CLL - Oncodaily
-
AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up - Fierce Pharma
-
Fixed-Duration AV Is a Compelling Option, With Important Caveats: Adam Kittai, MD - The American Journal of Managed Care
-
Calquence Plus Venclexta: FDA Approves First All‑Oral Fixed‑Duration Regimen for Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - WebMD
-
Zanubrutinib Outperforms Acalabrutinib in Indirect Comparison for R/R CLL - Oncology Nurse Advisor
-
FDA Approves Calquence in Combination with Venetoclax for Treatment of Adults with Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma - Pharmaceutical Executive
-
Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL - OncLive
-
AV Gives CLL Patients a Fixed-Duration Oral Path: Adam Kittai, MD - The American Journal of Managed Care
-
Zanubrutinib showed a higher response rate than other BTK inhibitors in B-cell lymphomas - Managed Healthcare Executive
-
Relapsed or refractory mantle cell lymphoma: zanubrutinib shows longer survival than acalabrutinib in real-world use - Vera Health
-
Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet
-
Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma - OncLive
-
Indirect Comparison Finds Zanubrutinib Associated With Better PFS, OS Than Acalabrutinib in MCL - The American Journal of Managed Care
-
FDA Clears All-Oral Doublet for First-Line CLL/SLL - Clinical Oncology News
-
All-oral Calquence, Venclexta combo clinches FDA nod in first-line CLL - FirstWord Pharma
-
NICE recommends AstraZeneca's Calquence for two blood cancers in England and Wales - The Pharma Letter
-
NICE recommends new treatment for Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia - National Health Executive
-
Prior Ibrutinib May Improve CAR-T Efficacy in Rare Lymphoma - MedPage Today
-
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial - Nature
-
Is This Drug Combo the Future of Chronic Lymphocytic Leukemia Care? - Medscape
-
FDA Approves AstraZeneca Oral Treatment for Lymphocytic Leukemia and Lymphoma - Contract Pharma
-
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial - Nature
-
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia - The New England Journal of Medicine
-
Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes - OncLive
-
Acalabrutinib: A Favorable Safety Profile in BTK Inhibition - Targeted Oncology
-
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL - OncLive
-
Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL - The American Journal of Managed Care
-
Recent Developments in Chronic Lymphocytic Leukemia - MedPage Today
-
Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting - AstraZeneca
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.